Differential expression of tissue inhibitors of metalloproteinases in the failing human heart

Circulation

Volumn 98, Issue 17, 1998, Pages 1728-1734

  Li, Yun You ^a   Feldman, Arthur M ^a   Sun, Yi ^b   McTiernan, Charles F ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

Heart failure; Metalloproteinases; Remodeling

Indexed keywords

GELATIN; GELATINASE B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; POLYADENYLATED RNA; TISSUE INHIBITOR OF METALLOPROTEINASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; HEART FAILURE; HUMAN; HUMAN TISSUE; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 0001751017     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.17.1728     Document Type: Article

References (31)

1. Brilla CG, Rupp H. Myocardial collagen matrix remodeling and congestive heart failure. Cardiologia. 1994;39:389-393.
2. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, Quaini F, Sonnenblick EH, Olivetti G, Anversa P. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation. 1994;89:151-163.
3. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83: 1849-1865.
4. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995;77:863-868.
5. Tyagi SC, Campbell SE, Reddy HK, Tjahja E, Voelker DJ. Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem. 1996;155: 13-21.
6. Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem. 1996;271:30375-30380.
7. Fabunmi RP, Baker AH, Murray EJ, Booth RF, Newby AC. Divergent regulation by growth factors and cytokines of 95-kDa and 72-kDa gelatinases and tissue inhibitors of metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. Biochem J. 1996;315:335-342.
8. Li YY, McTiernan CF, Feldman AM. IL-1β alters the expression of the receptor tyrosine kinase gene r-EphA3 in neonatal rat cardiomyocytes. Am J Physiol. 1998;274:H331-H341.
9. Tyagi SC, Kumar SG, Haas SJ, Reddy HK, Voelker DJ, Hayden MR, Demmy TL, Schmaltz RA, Curtis JJ. Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J Mol Cell Cardiol. 1996;28: 1415-1428.
10. Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF Jr. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy: role of metalloproteinases and pyridinoline cross-links. Am J Pathol. 1996; 148:1639-1648.
11. McTiernan CF, Lemster BH, Frye C, Brooks S, Combes A, Feldman AM. Interleukin-1β inhibits phospholamban gene expression in cultured cardiomyocytes. Circ Res. 1997;81:493-503.
12. Sun Y, Hegamyer G, Kim H, Sithanandam K, Li H, Watts R, Colburn NH. Molecular cloning of mouse tissue inhibitor of metalloproteinases-3 and its promoter: specific lack of expression in neoplastic JB6 cells may reflect altered gene methylation. J Biol Chem. 1995;270:19312-19319.
13. Tyagi SC, Matsubara L, Weber KT. Direct extraction and estimation of collagenase(s) activity by zymography in microquantities of rat myocardium and uterus. Clin Biochem. 1993;26:191-198.
14. Wallenstein S, Zucker CL, Fleiss JL. Some statistical methods useful in circulation research. Circ Res. 1980;47:1-9.
15. Ogata Y, Itoh Y, Nagase H. Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem. 1995;270:18506-18511.
16. Itoh Y, Nagase H. Preferential inactivation of tissue inhibitor of metalloproteinases-1 that is bound to the precursor of matrix metalloproteinase 9 (progelatinase B) by human neutrophil elastase. J Biol Chem. 1995;270:16518-16521.
17. Weber KT. The healing wound: a case for extracellular matrix. Heart Failure Rev. 1996;1:53-62.
18. Tyagi SC, Kumar S, Voelker DJ, Reddy HK, Janicki JS, Curtis JJ. Differential gene expression of extracellular matrix components in dilated cardiomyopathy. J Cell Biochem. 1996;63:185-198.
19. Armstrong PW, Moe GW, Howard RJ, Grima EA, Cruz TF. Structural remodelling in heart failure: gelatinase induction. Can J Cardiol. 1994; 10:214-220.
20. De Clerck YA, Darville MI, Eeckhout Y, Rousseau GG. Characterization of the promoter of the gene encoding human tissue inhibitor of metalloproteinases-2 (TIMP-2). Gene. 1994;139:185-191.
21. Wick M, Haronen R, Mumberg D, Burger C, Olsen BR, Budarf ML, Apte SS, Muller R. Structure of the human TIMP-3 gene and its cell cycle-regulated promoter. Biochem J. 1995;311:549-554.
22. DiBattista JA, Pelletier JP, Zafarullah M, Iwata K, Martel-Pelletier J. Interleukin-1 beta induction of tissue inhibitor of metalloproteinase (TIMP-1) is functionally antagonized by prostaglandin E2 in human synovial fibroblasts. J Cell Biochem. 1995;57:619-629.
23. MacNaul KL, Chartrain N, Lark M, Tocci MJ, Hutchinson NI. Differential effects of IL-1 and TNF alpha on the expression of stromelysin, collagenase and their natural inhibitor, TIMP, in rheumatoid human synovial fibroblasts. Matrix. 1992;1(suppl):198-199.
24. Shingu M, Nagai Y, Isayama T, Naono T, Nobunaga M, Nagai Y. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol. 1993;94:145-149.
25. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201-1206.
26. Bigg HF, Shi YE, Liu YE, Steffensen B, Overall CM. Specific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal hemopexin-like domain of human gelatinase A: TIMP-4 binds progelatinase A and the COOH-terminal domain in a similar manner to TIMP-2. J Biol Chem. 1997;272:15496-15500.
27. Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol. 1995;27:1281-1292.
28. Bodden MK, Windsor LJ, Caterina NC, Harber GJ, Birkedal-Hansen B, Birkedal-Hansen H. Human TIMP-1 binds to pro-M(r) 92K GL (gelatinase B, MMP-9) through the "second disulfide knot." Ann N Y Acad Sci. 1994;732:403-407.
29. Okada Y, Gonoji Y, Naka K, Tomita K, Nakanishi I, Iwata K, Yamashita K, Hayakawa T, Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells: purification and activation of the precursor and enzymic properties. J Biol Chem. 1992; 267:21712-21719.
30. Mohtai M, Smith RL, Schurnian DJ, Tsuji Y, Torti FM, Hutchinson NI, Stetler-Stevenson WG, Goldberg GI. Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1. J Clin Invest. 1993;92:179-185.
31. Tyagi SC, Kumar SG, Banks J, Fortson W. Co-expression of tissue inhibitor and matrix metalloproteinase in myocardium. J Mol Cell Cardiol. 1995;27:2177-2189.